On Friday, Phathom Pharmaceuticals Inc (NASDAQ: PHAT) was -4.73% drop from the session before settling in for the closing price of $7.82. A 52-week range for PHAT has been $6.07 – $19.71.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at -37.62%. With a float of $34.87 million, this company’s outstanding shares have now reached $68.32 million.
The firm has a total of 452 workers. Let’s measure their productivity. In terms of profitability, gross margin is 85.02%, operating margin of -1096.02%, and the pretax margin is -1292.14%.
Phathom Pharmaceuticals Inc (PHAT) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Phathom Pharmaceuticals Inc stocks. The insider ownership of Phathom Pharmaceuticals Inc is 49.01%, while institutional ownership is 69.11%. The most recent insider transaction that took place on Dec 19 ’24, was worth 8,944. In this transaction Chief Operating Officer of this company sold 1,118 shares at a rate of $8.00, taking the stock ownership to the 239,303 shares. Before that another transaction happened on Dec 19 ’24, when Company’s CFO and CBO sold 1,291 for $8.00, making the entire transaction worth $10,328. This insider now owns 98,156 shares in total.
Phathom Pharmaceuticals Inc (PHAT) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -37.62% per share during the next fiscal year.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Trading Performance Indicators
You can see what Phathom Pharmaceuticals Inc (PHAT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.68. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 18.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.69, a number that is poised to hit -1.21 in the next quarter and is forecasted to reach -4.09 in one year’s time.
Technical Analysis of Phathom Pharmaceuticals Inc (PHAT)
Analysing the last 5-days average volume posted by the [Phathom Pharmaceuticals Inc, PHAT], we can find that recorded value of 1.27 million was better than the volume posted last year of 0.92 million. As of the previous 9 days, the stock’s Stochastic %D was 7.44%. Additionally, its Average True Range was 0.78.
During the past 100 days, Phathom Pharmaceuticals Inc’s (PHAT) raw stochastic average was set at 0.49%, which indicates a significant decrease from 2.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 60.05% in the past 14 days, which was lower than the 90.36% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.24, while its 200-day Moving Average is $12.13. Now, the first resistance to watch is $7.72. This is followed by the second major resistance level at $8.00. The third major resistance level sits at $8.16. If the price goes on to break the first support level at $7.28, it is likely to go to the next support level at $7.12. Now, if the price goes above the second support level, the third support stands at $6.84.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Key Stats
There are 68,377K outstanding shares of the company, which has a market capitalization of 485.31 million. As of now, sales total 680 K while income totals -201,590 K. Its latest quarter income was 16,350 K while its last quarter net income were -85,580 K.
